GoAI
Get started
Haleon plc logo

Haleon plc

HLN

NYSEHealthcareDrug Manufacturers - Specialty & Generic

Open in GoAI

Previous close

$10.00

+$0.13 · +1.32%

Aug 21, 4:00 PM ET

Pre-market

$9.98

−$0.02 · -0.20%

Aug 24, 8:17 AM ET

HLN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

88

Deep Value

Momentum

42

Neutral

Sentiment

52

Mixed

Risk resilience

78

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Headquarters
GB
CEO
Brian James McNamara
Listed since
Jul 25, 2022
Employees
24,535

Market position

Day range

Current $10.00

52-week range

Current $10.00

Open
$9.91
Previous close
$9.87
Volume
7.17M
0.77× average
Average volume
9.37M
Average daily volume
Market cap
44.04B USD
Beta
0.25
Market reference 1
50-day average
$9.667
+3.44% above average
200-day average
$9.8243
+1.79% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
40.89B GBP
P/E (TTM)
19.98×
P/B (TTM)
1.97×
P/S (TTM)
2.86×
EV / EBITDA
14.2×
Earnings yield
4.85%
Free cash flow yield
5.86%
Dividend yield
1.27%

Profitability & efficiency

Gross margin
65.57%
Operating margin
21.35%
Net margin
14.55%
Return on equity
9.94%
Return on assets
5.01%
Return on invested capital
6.64%

Financial health

Debt / equity
0.5×
Current ratio
0.92×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends69%47%26%4%Gross margin, FY2021: 62.34%Gross margin, FY2022: 60.57%Gross margin, FY2023: 61.59%Gross margin, FY2024: 61.85%Gross margin, FY2025: 63.35%Operating margin, FY2021: 17.16%Operating margin, FY2022: 16.81%Operating margin, FY2023: 17.66%Operating margin, FY2024: 19.64%Operating margin, FY2025: 21.87%Net margin, FY2021: 14.56%Net margin, FY2022: 9.76%Net margin, FY2023: 9.28%Net margin, FY2024: 12.84%Net margin, FY2025: 14.78%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 62.34%. Gross margin FY2022 60.57%. Gross margin FY2023 61.59%. Gross margin FY2024 61.85%. Gross margin FY2025 63.35%. Operating margin FY2021 17.16%. Operating margin FY2022 16.81%. Operating margin FY2023 17.66%. Operating margin FY2024 19.64%. Operating margin FY2025 21.87%. Net margin FY2021 14.56%. Net margin FY2022 9.76%. Net margin FY2023 9.28%. Net margin FY2024 12.84%. Net margin FY2025 14.78%.

Income trends

Revenue

11.03B GBP-1.81%

Operating income

2.41B GBP+9.34%

Net income

1.63B GBP+13.07%
Income trends across reported periods12.33B GBP8.23B GBP4.12B GBP23.7M GBPRevenue, FY2021: 9.55B GBPRevenue, FY2022: 10.86B GBPRevenue, FY2023: 11.3B GBPRevenue, FY2024: 11.23B GBPRevenue, FY2025: 11.03B GBPOperating income, FY2021: 1.64B GBPOperating income, FY2022: 1.83B GBPOperating income, FY2023: 2B GBPOperating income, FY2024: 2.21B GBPOperating income, FY2025: 2.41B GBPNet income, FY2021: 1.39B GBPNet income, FY2022: 1.06B GBPNet income, FY2023: 1.05B GBPNet income, FY2024: 1.44B GBPNet income, FY2025: 1.63B GBPFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 9.55B GBP. Revenue FY2022 10.86B GBP. Revenue FY2023 11.3B GBP. Revenue FY2024 11.23B GBP. Revenue FY2025 11.03B GBP. Operating income FY2021 1.64B GBP. Operating income FY2022 1.83B GBP. Operating income FY2023 2B GBP. Operating income FY2024 2.21B GBP. Operating income FY2025 2.41B GBP. Net income FY2021 1.39B GBP. Net income FY2022 1.06B GBP. Net income FY2023 1.05B GBP. Net income FY2024 1.44B GBP. Net income FY2025 1.63B GBP.
Metric (GBP)FY2025FY2024FY2023FY2022FY2021
Revenue11.03B GBP11.23B GBP11.3B GBP10.86B GBP9.55B GBP
Cost of goods sold3.83B GBP4.29B GBP4.34B GBP4.28B GBP3.6B GBP
Gross profit6.99B GBP6.95B GBP6.96B GBP6.58B GBP5.95B GBP
Research and development308.1M GBP298M GBP311M GBP300M GBP257M GBP
Selling, general, and administrative4.36B GBP4.33B GBP4.29B GBP4.04B GBP3.79B GBP
Operating expenses4.43B GBP4.74B GBP4.97B GBP4.75B GBP4.31B GBP
Interest income76.29M GBP55M GBP14M GBP68.98M GBP13M GBP
Interest expense332.55M GBP394M GBP414M GBP347.36M GBP16M GBP
Depreciation and amortization352.11M GBP196M GBP309M GBP287M GBP268M GBP
Operating income2.41B GBP2.21B GBP2B GBP1.83B GBP1.64B GBP
Net income1.63B GBP1.44B GBP1.05B GBP1.06B GBP1.39B GBP

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
0.36
FY2025 · +12.50% year over year
Latest fiscal-year revenue
11.03B GBP
FY2025 · -1.81% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend0.370.320.280.23FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend11.48B10.77B10.07B9.37BFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$10.20

2.00% upside
Past 12 months12-month forecastHigh $10.20Average $10.20Low $10.20

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

HLN news

prnewswire.com

Haleon plc: Announces Pricing Terms, Expiration and Results of its Cash Tender Offer for outstanding 2027 Notes

LONDON, Aug. 19, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the pricing terms, expiration and results of the offer to buy back any and all of the outstanding…

Read source
prnewswire.com

Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes

LONDON, Aug. 11, 2026 /PRNewswire/ -- Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of…

Read source
defenseworld.net

Haleon plc (LON:HLN) Receives Average Recommendation of “Hold” from Analysts

Haleon plc (LON: HLN - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock…

Read source
seekingalpha.com

Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript

Haleon plc (HLN) Q2 2026 Earnings Call Prepared Remarks Transcript

Read source
zacks.com

ACCO vs. HLN: Which Stock Is the Better Value Option?

Investors with an interest in Consumer Products - Discretionary stocks have likely encountered both Acco Brands (ACCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option for those…

Read source
proactiveinvestors.com

Haleon slides as quality of growth questioned

Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 2.9% to 368.7p after the consumer healthcare group reported improving second-quarter sales but left its full-year...

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$0.1764

2025 complete year+70.1% since 2023

2026 partial: $0.0642

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Aug 14, 2026

$0.0642

Semi-Annual

Record Aug 14, 2026 · Payment Sep 17, 2026

Dividend

Ex-dividend Aug 15, 2025

$0.0598

Semi-Annual

Record Aug 15, 2025 · Payment Sep 18, 2025

Dividend

Ex-dividend Apr 25, 2025

$0.1166

Semi-Annual

Record Apr 25, 2025 · Payment Jun 5, 2025

Dividend

Ex-dividend Aug 16, 2024

$0.0514

Semi-Annual

Record Aug 16, 2024 · Payment Sep 19, 2024

Dividend

Ex-dividend Mar 14, 2024

$0.1064

Semi-Annual

Record Mar 15, 2024 · Payment May 16, 2024

Dividend

Ex-dividend Aug 24, 2023

$0.046

Semi-Annual

Record Aug 25, 2023 · Payment Oct 5, 2023

HLN peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

Novartis AG logo

NVS

Novartis AG

$158.86

+1.68%

ETFs holding HLN

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR Portfolio Developed World ex-US ETF logoState Street SPDR Portfolio Developed World ex-US ETFSPDW
Market value
54.13M
Weight
0.13%
AUM
41.92B USD
Expense ratio
0.03%
Price / 1D
$52.02+0.79%
VanEck Pharmaceutical ETF logoVanEck Pharmaceutical ETFPPH
Market value
32.88M
Weight
3.11%
AUM
1.07B USD
Expense ratio
0.36%
Price / 1D
$116.63+1.35%
GMO International Quality ETF logoGMO International Quality ETFQLTI
Market value
10.85M
Weight
3.60%
AUM
298M USD
Expense ratio
0.60%
Price / 1D
$27.96+0.90%
Avantis International Equity ETF logoAvantis International Equity ETFAVDE
Market value
8.95M
Weight
0.05%
AUM
19.1B USD
Expense ratio
0.23%
Price / 1D
$94.26+0.87%
Fidelity Enhanced International ETF logoFidelity Enhanced International ETFFENI
Market value
7.05M
Weight
0.06%
AUM
10.96B USD
Expense ratio
0.28%
Price / 1D
$41.72+0.77%
Portfolio Building Block World Pharma and Biotech Index ETF logoPortfolio Building Block World Pharma and Biotech Index ETFPBPH
Market value
6.2M
Weight
0.59%
AUM
933.15M USD
Expense ratio
0.13%
Price / 1D
$29.5672+1.22%
Franklin ClearBridge Enhanced Income ETF logoFranklin ClearBridge Enhanced Income ETFYLDE
Market value
4.01M
Weight
2.33%
AUM
172.83M USD
Expense ratio
0.48%
Price / 1D
$57.6393+0.39%
Scharf Global Opportunity ETF logoScharf Global Opportunity ETFGKAT
Market value
3.81M
Weight
2.23%
AUM
132M USD
Expense ratio
0.59%
Price / 1D
$46.1113+0.55%

Continue in GoAI

Research HLN

research.disclaimer